Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride
NEW ORLEANS, June 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sugar and...
New Diabetes Drug Shows Promise in Trial
mimics effects of a natural hormone, researchers s...hDay News) -- An experimental diabetes drug called liraglutide
appears to outperform exenatide (Byetta), the only...ed by liraglutide's maker, Novo Nordisk, shows.
is a laboratory-made version of glucagon-like pept...
A Weight Neutral Oral Antidiabetic Drug Would Earn a 25 Percent Patient Share in the Type 2 Diabetes Drug Market
... Advantages in Efficacy and Safety Will Make liraglutide
the New Clinical Gold Standard Drug by 2011, Acco...n over Hypoglycemia also finds that Novo
will become the new Decision Resources' proprietar... as
surveyed primary care physicians indicate that liraglutide
advantages in terms of efficacy an...
Pipeline for New Obesity Therapies is Focus of New Report
...ylin/Alkermes), exenatide + recombinant leptin (r-metHuLeptin;
Amylin/Amgen), Symlin (pramlintide; Amylin), pramlintide + AC162352 (PYY
3-36; Amylin), liraglutide
(NN2211; Novo Nordisk), albiglutide (GSK / Human
Genome Science), PC-DAC:Exendin-4 (ConjuChem), Boc5 (SH-7871; UC Riverside
/ Chinese Academy of Scien...
Endocrinology Panel Examines Interplay Between Diabetes and Cardiovascular Disease in New Report
... (Amylin), pramlintide + leptin
(Amylin/Amgen), Galvus (vildagliptin; Novartis), alogliptin (Takeda),
saxagliptin (BMS/AZ), Redona (denagliptin; GSK), liraglutide
Nordisk), Boc5 (UC Riverside / Chinese Acad. Sci.), substituted
quinoxalines (Pfizer/Novo Nordisk), Actos (pioglitazone; Takeda/Lilly),
Liraglutide in Medical Technology
The Lancet Publishes Direct Comparison Study Between Liraglutide and Exenatide
NEW ORLEANS, June 8 /PRNewswire/ -- Today, The Lancet published online the results of the Novo Nordisk (NVO) LEAD(TM) 6 study, a direct comparison between two products in a new class of diabetes treatments, the GLP-1 receptor agonists. Results show that patients treated with liraglutide
Two-Year Data Show Investigational Drug Liraglutide More Effective at Lowering Blood Sugar Than Glimepiride: Oral 162
NEW ORLEANS, June 7 /PRNewswire-FirstCall/ -- Novo Nordisk (NVO) data presented today at the 69th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily liraglutide, taken as monotherapy, leads to statistically significant and sustained reductions in blood sug...
Update on FDA Advisory Committee Meeting on Liraglutide for the Treatment of Type 2 Diabetes
SILVER SPRING, Md., April 2 /PRNewswire-FirstCall/ -- Novo Nordisk today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the United States Food and Drug Administration (FDA) has finalized its discussions of questions related to liraglutide, a once-daily human GLP-1 anal...
Data from One-Year Liraglutide Phase 3 Study Published Online in The Lancet
PRINCETON, N.J., Sept. 25 /PRNewswire/ -- Data from a 52-week phase 3
study (LEADTM 3) of Novo Nordisk's (NYSE: NVO ) liraglutide, a once-daily
human GLP-1 analog, were published online today in The Lancet. The study
showed that liraglutide, when taken alone, produces statistically
Novo Nordisk New Data From a Phase 3 Study Confirms Clinical Benefits of Once-Daily Liraglutide in the Management of Type 2 Diabetes
ROME, Sept. 8 /PRNewswire-FirstCall/ -- Novo Nordisk (NYSE: NVO ), a
global healthcare company, presented data from a phase 3 clinical study
(LEAD(TM) 4) today at the 44th annual meeting of the European Association
for the Study of Diabetes that demonstrated adding the investigational new
Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide
SAN FRANCISCO, June 9 /PRNewswire-FirstCall/ -- Data presented today at
the 68th Scientific Sessions of the American Diabetes Association (ADA)
demonstrated that once-d...
Liraglutide provides significantly better glucose control than
insulin glargine in phase 3 study
...esults from the first of five phase 3 studies with liraglutide
the once-daily human GLP-1 analogue. The 26-week...end of the study, more than 50% of
patients in the liraglutide
group had reached the American Diabetes
Associatio...e study, the difference in
body weight between the liraglutide
and insulin glargine treatment
groups was on avera...
Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog
Liraglutide, Brings Patients to A1c Target
...ted over a period of 14 weeks. Results
showed that liraglutide
was effective and well tolerated within a
wide dos... considerable advance in diabetes treatment."
acts to lower blood glucose when levels are
receive one of four once-daily doses of liraglutide
(0.1, 0.3, 0.6,
and 0.9 mg) or placebo. Baseline A...
Liraglutide in Biological Technology